{"title":"治疗中度至重度溃疡性结肠炎的米利珠单抗","authors":"Steve Chaplin","doi":"10.1002/psb.2131","DOIUrl":null,"url":null,"abstract":"Mirikizumab (Omvoh) is an anti‐IL‐23 monoclonal antibody for the treatment of moderate to severe ulcerative colitis. This article outlines its administration, clinical trial efficacy, adverse effects and place in therapy.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mirikizumab for moderate to severe ulcerative colitis\",\"authors\":\"Steve Chaplin\",\"doi\":\"10.1002/psb.2131\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mirikizumab (Omvoh) is an anti‐IL‐23 monoclonal antibody for the treatment of moderate to severe ulcerative colitis. This article outlines its administration, clinical trial efficacy, adverse effects and place in therapy.\",\"PeriodicalId\":20432,\"journal\":{\"name\":\"Prescriber\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/psb.2131\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Mirikizumab for moderate to severe ulcerative colitis
Mirikizumab (Omvoh) is an anti‐IL‐23 monoclonal antibody for the treatment of moderate to severe ulcerative colitis. This article outlines its administration, clinical trial efficacy, adverse effects and place in therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
